- Home
- SHOE vs EYPT Comparison
SHOE vs EYPT Comparison
Compare SHOE & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOE | EYPT |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.5M | 419.9M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SHOE | EYPT |
|---|---|---|
| Price | $14.07 | $4.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 665.8K | ★ 6.3M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,135,324,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.78 | $3.95 |
| 52 Week High | $16.29 | $19.11 |
Technical Indicators
Market Signals| Indicator | SHOE | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 29.97 |
| Support Level | N/A | $3.95 |
| Resistance Level | $16.01 | $15.17 |
| Average True Range (ATR) | 0.60 | 0.51 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 25.12 | 26.30 |
Price Performance
Historical ComparisonAbout SHOE Shoe Station Group Inc. Common Stock
Shoe Station Group Inc is a one-stop family footwear destination that offers an impressive selection from top brands. It is a fashion destination for footwear, southern-inspired accessories, and apparel. The group has physical stores throughout five Southern states and is available online at ShoeStation.com, shipping all across the U.S. Its offer products for Women's, Men's, and Kids.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.